The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada
| Autor: | Paul Brassard, Marc Steben, Caroline Rodier, Liliya Sinyavskaya, Najwa Ouhoummane |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Immunity Herd Male 0301 basic medicine Canada medicine.medical_specialty Adolescent 030106 microbiology Population Imiquimod Antiviral Agents Herd immunity Young Adult 03 medical and health sciences Sex Factors 0302 clinical medicine Virology Epidemiology Humans Medicine Papillomavirus Vaccines 030212 general & internal medicine Medical prescription Child education Papillomaviridae education.field_of_study Immunization Programs business.industry Incidence Incidence (epidemiology) Papillomavirus Infections Vaccination Age Factors Quebec Infectious Diseases Condylomata Acuminata Female Diagnosis code Warts business medicine.drug |
| Zdroj: | Journal of Medical Virology. 90:592-598 |
| ISSN: | 0146-6615 |
| DOI: | 10.1002/jmv.24968 |
| Popis: | In Québec province in Canada, a public school-based and catch-up HPV vaccination programs with the quadrivalent vaccine have been introduced in September 2008 for girls aged 9-17 years. We assessed the early impact of the HPV vaccination program on the incidence of anogenital warts (AGW) in the Quebec general population. We used the provincial health administrative data of the Régie de l'assurance maladie du Québec (RAMQ). AGW were identified either through a prescription of podofilox, or a medical procedure code specific to AGW, or a diagnostic code for viral warts followed by a prescription of imiquimod or fluorouracil. Sex- and age-specific incidence rates were calculated for pre-vaccination (2004-2007) and vaccination (2009-2012) periods. We found a significant decline of 45% and 19% in the incidence of AGWs among females aged 15-19 and 20-24 years, respectively. A decline of 21% was also seen among males aged 15-19 years. The median age at an episode of AGW increased from 27 years in 2004 to 31 years in 2012 among females and remained stable in males. Our findings indicate that the HPV public vaccination program is associated with an important reduction in the incidence of AGW among young females and males. The benefit is more pronounced among females 15-19 years of age, who were eligible for the public vaccination program. The observed decline among young males could be due to herd immunity and/or privately paid vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text